Baker Bros. Advisors Ups Stake in Seattle Genetics Inc. (SGEN)

Baker Bros. Advisors, managed by Julian Baker and Felix Baker, have disclosed raising its stake in Seattle Genetics Inc. (NASDAQ:SGEN). In a new filing with the U.S. Securities and Exchange Commission, Baker Bros. Advisors revealed that it brought the stake to 21.63 million shares, which represent 17.5% of common stock outstanding. In another filing, Baker Bros reported acquiring around 231,100 shares in market transactions and following conversion of stock options.

Seattle Genetics, Inc. (NASDAQ:SGEN)Felix J. Baker entered into a proceeds agreement with the fund on May 12, 2014, pursuant to the which he agreed that, with respect to the exercised stock options and the common stock received as a result of the exercise of the exercised stock options, the fund will have dispositive power as well as the ability to control the timing of exercise of the exercised stock options and that any proceeds from the sale of the common stock will be remitted to the fund net of brokerage commissions. Other than through their control of the fund, Baker and Julian C. Baker have neither voting nor dispositive power and have no direct pecuniary interest in the exercised stock options or the common stock.

Aside from Baker Bros, Jim Simons‘ Renaissance Technologies is another hedge fund bullish on Seattle Genetics. According to the fund’s latest 13F filing, Renaissance currently owns around 268,700 shares of the company, up by 142,700 shares in comparison to the previous filing. On the other hand, Israel Englander‘s Millennium Management significantly cut its stake in the company, by over 70%, to some 42,200 shares.

Baker Bros. Advisors focuses mainly on biotechnology companies. At the beginning of the year, the fund decreased its stake in MEI Pharma Inc (NASDAQ:MEIP) to 746,521 shares from 1,130,317 shares revealed as held earlier.

Disclosure: none

Recommended Reading:

Hedge Fund Highlights: Chase Coleman, Daniel Loeb & David Tepper

Hedge Fund News: John Burbank, Phil Falcone & Jim Rogers

Julian Robertson Top Three Largest New Positions

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!